While testing the effect of the (β15-66) 2 fragment, which mimics two fibrin βN-domains, on the morphology of endothelial cells, we found that this fragment induces redistribution of VE-cadherin in a process that is inhibited by the receptor-associated protein (RAP). Based on this finding, we hypothesized that fibrin may interact with members of RAP-dependent LDL receptor family. To test this hypothesis, we examined the interaction of (β15-66) 2 , fibrin, and several fibrin-derived fragments with two members of this family by ELISA and surface plasmon resonance. The experiments revealed that one of them, the VLDL receptor (VLDLR), interacts with high affinity with fibrin through its βN-domains, and this interaction is inhibited by RAP and (β15-66) 2 .
Introduction
Thrombin-mediated conversion of fibrinogen into fibrin plays a prominent role in preventing the loss of blood upon vascular injury. During this conversion, thrombin removes from fibrinogen two pairs of N-terminal fibrinopeptides, fibrinopeptide A (FpA) and fibrinopeptide B (FpB), enabling spontaneous polymerization of fibrin monomers into an insoluble fibrin clot. The clot seals the injured vasculature and serves as a provisional matrix that participates in subsequent wound healing and other important physiological and pathological processes through the interaction with various plasma proteins and cell types. Specifically, the interaction of fibrin with endothelial cells contributes to anchoring of the clot to places of vascular injury and then promotes transendothelial migration of leukocytes and thereby inflammation and capillary tube formation, i.e. angiogenesis. [1] [2] [3] [4] There are several receptors on the endothelial cell surface that mediate the interaction of fibrin(ogen) with endothelial cells. They include integrins αVβ3, αVβ5, and α5β1, [5] [6] [7] and nonintegrin receptors ICAM-1, VE-cadherin, and proteoglycans. [8] [9] [10] The interaction of endothelial cell integrins with fibrin(ogen) occurs mainly through the fibrin(ogen) RGD sequences and promotes endothelial cell adhesion and spreading. 5, 7 This interaction may also promote cell migration and angiogenesis. 3, 7 The interaction with proteoglycans mediates binding of fibrin(ogen) to endothelial cells 10 while that with ICAM-1 promotes adhesion and transendothelial migration of leukocytes. 2, 8 Leukocyte transmigration is also supported by the interaction of fibrin or its degradation products with VE-cadherin; 4,11 furthermore, this interaction was shown to promote fibrin-dependent angiogenesis. 9, 12 Fibrinogen is a complex multidomain protein whose multiple functions are carried out through the interaction of its individual domains with various proteins and cell types. Several fibrin (ogen) domains are involved in the interaction with endothelial cell receptors. Among them, two βN-For personal use only. on . by guest www.bloodjournal.org From domains, each formed by the N-terminal portion of the fibrin β chain, were shown to be responsible for the interaction with VE-cadherin. 13, 14 Previous studies revealed that the β15-42 sequence representing about half of the fibrin βN-domain is involved in the interaction with VE-cadherin and the exposure of this sequence after the removal of FpB (residues Bβ1-14) from fibrinogen is necessary for fibrin-dependent capillary tube formation. 1, 9, 12 Another study found that NDSK-II fragment, which corresponds to the central region of fibrin and contains the β15-42 sequence, induces leukocyte transmigration in vitro and a synthetic peptide β15-42 corresponding to this sequence inhibits this process. 11 To explain this finding, it was hypothesized that NDSK-II induces this process by bridging inflammatory cells to the endothelium through the interaction with CD11c receptor of the former and VE-cadherin of the latter and, therefore, the inhibitory effect of β15-42
was associated with its ability to compete with NDSK-II for the interaction with VE-cadherin. 4, 11 Our recent finding that dimeric β15-42 containing fragments inhibited infiltration of leukocytes into the peritoneum in a mouse model of peritonitis by more than 50% 15 highlights the importance of this mechanism in the overall transmigration of leukocytes during inflammation.
Although the above mentioned hypothesis coherently explains the inhibitory effect of the β15-42
peptide and its anti-inflammatory properties, it does not take into account the fact that the affinity of this peptide to VE-cadherin is very low. Our previous study revealed that even at the concentration of 1 μM this peptide did not exhibit any binding to VE-cadherin and only a dimeric fragment, (β15-66) 2 , corresponding to the full length βN-domain and mimicking its dimeric arrangement in fibrin bound VE-cadherin with high affinity. 13 Our recent study confirmed that the affinity of the β15-42
peptide to VE-cadherin is very low (K d = 267 μM). 15 At the same time, the affinity of this peptide to endothelial cell surface was found to be three orders of magnitude higher (K d = 0.18 μM). 12, 16 Based on these findings, we hypothesized that the β15-42 peptide and fibrin may interact with other
For personal use only. on . by guest www.bloodjournal.org From endothelial cell receptors and such interaction(s) may contribute to the anti-inflammatory effect of the former and proinflammatory effect of the latter. 15 In the present study, we found that fibrin interacts with endothelial cells through their VLDL receptor (VLDLR) and localized VLDLR-binding site in fibrin βN-domains. Our in vitro and in vivo experiments revealed that this interaction promotes fibrin-dependent transendothelial migration of leukocytes. Thus, we identified VLDLR as a novel endothelial cell receptor for fibrin which modulates fibrin-dependent leukocyte transmigration and thereby inflammation.
Materials and methods

Proteins, antibodies, and reagents
Human fibrinogen (plasminogen-, von Willebrand factor-, and fibronectin-depleted) was from Enzyme Research Laboratories (South Bend, IN). The soluble form of human VLDL receptor that contains the entire ectodomain (sVLDLR) was prepared using the Drosophila Expression System (Invitrogen) and purified as previously described. 17 Low-density lipoprotein receptor-related protein (LRP) was isolated from human placenta. 18 Human recombinant receptor-associated protein (RAP) was expressed in E. coli and purified as described. 19 
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TMB were from KPL (Gaithersburg, MD). Anti-VLDLR mAb 1H5, 5F3, and 1H10, and mAb 5A6 that recognizes the LRP light chain have been described. 17, 20 
Preparation of fibrin(ogen) fragments
The recombinant (β15-66) 2 fragment and synthetic (β15-44) 2 and scrambled (β15-44) 2 fragments were prepared as described earlier. 13, 15 The recombinant αC-fragment (residues Aα221-610)
corresponding to the fibrinogen αC region was produced in E. coli. 21 The fibrinogen-derived E 3 fragment and fibrin-derived D-D:E 1 complex, and D-D and E 1 fragments were prepared from plasmin digests of fibrinogen and fibrin, respectively. 22, 23 NDSK fragment corresponding to the central region of fibrinogen was prepared by digestion of human fibrinogen with CNBr. 9 NDSK-II fragment lacking fibrinopeptides A and B was prepared by incubation of NDSK with thrombinagarose as was described. 15 The purity of all fragments was confirmed by SDS-PAGE. All fragments used in cell and animal experiments were additionally purified on Detoxi-Gel column (Thermo Scientific) to remove endotoxin contamination. Final endotoxin levels determined using Limulus amebocyte lysate test QCL-1000 (Lonza, Walkersville, MD) did not exceed 0.1 EU/mg for all fragments tested.
Mice
Wild-type C57BL/6 mice aged 8-12 weeks were from the Jackson Laboratory (Bar Harbor, ME).
VLDLR-deficient (VLDLR -/-) mice on a mixed background were also obtained from the Jackson
Laboratory and bread to 10 generations with a C57BL/6 background. All mice were housed in a pathogen-free facility, and all procedures were performed with University of Maryland Institutional
Animal Care and Use Committee approval. 
Surface plasmon resonance (SPR) analysis
Interaction of fibrin(ogen) fragments with immobilized sVLDLR or LRP was studied by SPR using the BIAcore 3000 biosensor (BIAcore AB, Uppsala, Sweden), essentially as described previously. 14 Briefly, immobilization of sVLDLR and LRP to the CM5 sensor chip was performed using the amine coupling kit (GE Healthcare) according to the manufacturer's procedure. Binding experiments were performed in binding buffer HBS-P (GE Healthcare) containing 1 mM CaCl 2 . Fibrin(ogen) fragments were injected at the indicated concentrations and the association/dissociation between them and the immobilized receptors was monitored by the change in the SPR response. To regenerate the chip surface, complete dissociation of the complex was achieved by adding 100 mM H 3 PO 4 for 30 seconds followed by re-equilibration with the binding buffer. All experiments were repeated at least twice. Experimental data were analyzed using BIAevaluation 4.1 software supplied with the instrument. The dissociation equilibrium constant, K d , was calculated as
where k ass and k diss represent kinetic constants that were estimated by global analysis of the association/dissociation data using the 1:1 Langmurian interaction model (kinetic analysis). To confirm the kinetic analysis, K d was also estimated by analysis of the association data using the steady-state affinity model (equilibrium analysis).
Cell culture and treatments
Human umbilical vein endothelial cells (HUVECs) purchased from Lonza, were grown in EGM-2 complete media according to the manufacturer's instruction, and used at passage 4 to 6. The HL-60 promyelocytic cell line (American Type Culture Collection, Manassas, VA) was cultured and differentiated to a neutrophil-like lineage as described earlier. 15 Differentiated HL-60 cells were labeled with Calcein AM fluorescent dye (BD Biosciences) in serum-free IMDM medium. All cell lines were cultured or incubated at 37°C and 5% CO 2 .
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Immunofluorescence microscopy
HUVECs were grown on gelatin coated glass coverslips till confluency. After treatments with (β15-66) 2 or RAP, the cells were washed with phosphate-buffered saline (PBS) and fixed with solution containing 4% formaldehyde, 5% sucrose in PBS for 20 min at room temperature. The fixed cells were permeabilized with 0.4% Triton X-100 for 5 min, blocked with 5% goat serum for 1 hour, and then incubated with anti VE-cadherin mAb 55-7H1 at 6 μg/mL for 3 hours at 37 o C. Subsequently, the coverslips were washed with PBS and incubated with secondary Alexa568 conjugated anti mouse polyclonal antibody (3 μg/mL, Invitrogen) for 1 hour at 37 o C. FITC phalloidin (2 μg/mL) and TO-Pro3 dye (0.5 μg/mL) were included in secondary antibody mixture to stain actin filaments and nuclei. After washing, the coverslips were mounted onto glass slides using FluorSave Reagent (Calbiochem, La Jolla, CA) and viewed with Nikon Eclipse E800 microscope and Laser scanning system Radiance 2100 (Biorad/Carl Zeiss MicroImaging GmbH, Gottingen, Germany). The images were captured using the Radiance 2100 software.
Leukocyte transendothelial migration assay
Transendothelial migration experiments were performed using 24-well plates containing 8-μm pore size PET membrane inserts (BD Biosciences) as described earlier. 15 Briefly, HUVECs were seeded onto the insert membrane pre-coated with gelatin and grown to confluence for 3 days without 
Mouse model of peritonitis
Wild-type or VLDLR (-/-) mice (4-6 per group) were injected intraperitoneally with 3.85% Bacto 2 at 80 μM. Four hours after the injections, mice in each group were euthanized by CO 2 inhalation followed by cervical dislocation, injected intraperitoneally with 3 mL ice-cold PBS, and total lavage fluid was withdrawn after massaging their abdomens. The total leukocyte (neutrophil) number in the peritoneal lavage was determined with a hemocytometer.
Statistical analysis
Statistical analysis was performed using Student's t-test with a P value of less than 0.05 being considered significant. All statistical analyses were performed in SigmaPlot 8.0 software (Systat Software, San Jose, CA). 
Results
Effect of the (β15-66) 2 
fragment on endothelial cells
Previous studies revealed that the recombinant (β15-66) 2 fragment, which mimics the structure and functional properties of fibrin βN-domains, interacts with endothelial cell receptor VE-cadherin. 13, 15 To test the effect of this fragment on the morphology of endothelial cells in culture, we used confocal fluorescence microscopy. Human umbilical vein endothelial cells (HUVECs) were grown on gelatin coated glass cover slips to confluency and then incubated with 250 nM (β15-66) 2 
Effect of RAP on the (β15-66) 2 -induced redistribution of VE-cadherin in endothelial cells
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The observed redistribution of VE-cadherin may be connected with its internalization, although new synthesis of VE-cadherin, inhibition of its transit to the surface, or some other reasons cannot be excluded. Since the low density lipoprotein (LDL) receptor family members are known to bind and internalize a broad spectrum of various structurally unrelated ligands, 24 one can expect them to be involved in such redistribution/internalization. To test this speculation, we studied the effect of RAP, a well known inhibitor of the LDL receptor family members, 19, 25 on the (β15-66) 2 -induced redistribution of VE-cadherin in HUVECs in the experiments similar to those described above.
HUVECs grown to confluency were incubated with 250 nM (β15-66) 2 
Evidence for the interaction of fibrin βN-domains with the VLDL receptor
To determine if the VLDL receptor and/or LRP interact with (β15-66) 2 , we performed an ELISA. In this assay, increasing concentrations of the recombinant extracellular portion of the VLDL receptor (sVLDLR) or LRP were incubated with the immobilized (β15-66) 2 
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detected with the cocktail of specific anti-VLDLR monoclonal antibodies (mAb 1H5, mAb 5F3, and mAb 1H10) or anti-LRP mAb 5A6, respectively. The results revealed prominent binding of sVLDLR to immobilized (β15-66) 2 while LRP exhibited no binding (Figure 2A ). It should be noted that both sVLDLR and LRP used in these experiments were functionally active since in a control experiment they both bound RAP (not shown). The binding of sVLDLR to immobilized (β15-66) 2 was dose-dependent and the K d value determined for this binding was found to be 5.7 ± 0.4 nM (n = 2). The binding was specific since in the presence of RAP the interaction of sVLDLR with (β15-66) 2 was substantially reduced (Figure 2A, inset) . Similarly, sVLDLR bound to immobilized fibrin with K d = 9.2 ± 0.5 nM (n = 2) ( Figure 2B ) and this binding was significantly inhibited by RAP and the (β15-66) 2 fragment ( Figure 2B, inset) . These experiments clearly indicate that the VLDL receptor interacted with fibrin and its βN-domains with high affinity and this interaction was specific.
This finding was confirmed by surface plasmon resonance (SPR) experiments, in which, in contrast to the ELISA experiments, VLDLR and LRP were immobilized on the surface of a sensor chip while their binding partners were in solution. First, when (β15-66) 2 at 1 μM was added to immobilized sVLDLR or LRP, a prominent binding was observed only to sVLDLR ( Figure 3A) . Second, when increasing concentrations of (β15-66) 2 were added to immobilized sVLDLR, the binding of this fragment was dose-dependent ( Figure 3B ) and the K d determined by the kinetic analysis (see Materials and methods) was found to be 3.6 ± 0.9 nM (n = 4), i.e. very close to that determined by ELISA. Finally, when (β15-66) 2 and RAP were injected individually at 500 nM and 50 nM, respectively, they both exhibited prominent binding to immobilized sVLDLR; however, when they were injected simultaneously at the same molar concentrations, the SPR signal was almost the same as that for RAP alone ( Figure 4A ) indicating that RAP inhibited the interaction of (β15-66) 2 with sVLDLR. In agreement, when a mixture of RAP and (β15-66) 2 
was injected after
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RAP or after (β15-66) 2 , the SPR signal was also almost the same as that for RAP alone ( Figure 4B ).
Altogether, these experiments indicate that the (β15-66) 2 fragment bound to the VLDL receptor with high affinity and the binding was highly specific.
Testing the interaction of other fibrin(ogen) fragments with the VLDL receptor
The (β15-66) 2 fragment corresponds to the fibrin βN-domains representing only a small portion of the molecule. To test if other fibrin regions/domains are involved in the interaction with the VLDL receptor, we studied binding of the latter with the proteolytically prepared fibrin fragments, D-D and E 1 , and the recombinant Aα221-610 fragment corresponding to the fibrin(ogen) αC regions. These fragments together cover practically the whole fibrin molecule. In SPR experiments, when these fragments, each at 1 μM, were added to the immobilized VLDL receptor, only E 1 exhibited a prominent binding while D-D and Aα221-610 failed to bind ( Figure 5 ). In addition, the E 3 fragment devoid of the βN-domains 23 exhibited no interaction with sVLDLR. In another experiment, when the D-D:E 1 complex prepared from the early digest of fibrin 22 and mimicking the arrangement and interactions of the D and E regions in the latter, was added to the immobilized VLDL receptor, it also exhibited a prominent binding, most probably through its E 1 component ( Figure 5 ). It should be noted that the same fragments failed to bind to immobilized LRP in similar experiments (not shown) further confirming that fibrin does not interact with this receptor. Altogether, these experiments indicate that the βN-domains are the only structures in fibrin that interact with the VLDL receptor.
They also suggest that these domains are reactive in fibrin.
Effect of RAP on transendothelial migration of leukocytes in vitro
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The interaction of NDSK-II, a fibrin fragment containing a pair of the βN-domains, with VEcadherin has been suggested to promote transendothelial migration of leukocytes and the β15-42 fragment derived from these domains has been shown to inhibit this process. 11 Our recent study confirmed this finding and revealed that the dimeric version of β15-42, the (β15-44) 2 fragment, as well as (β15-66) 2 dimer, are even more potent inhibitors of this process. 15 Furthermore, the data presented in this study indicates that the (β15-66) 2 fragment caused loosening and even disruption of cell-cell junctions in HUVEC ( Figure 1D and H) , which, in principle, may affect leukocyte transmigration. Since this effect was inhibited by RAP, we reasoned that RAP may also inhibit leukocyte transmigration. To test this hypothesis, we used an in vitro transendothelial leukocyte migration assay, in which transmigration of DMSO-induced HL-60 cells mimicking neutrophils 26 through HUVEC monolayer was induced by NDSK-II corresponding to the central region of fibrin.
It should be noted that such cells were shown to constitute a valid model system for the analysis of human neutrophil migration. 26 The results presented in Figure 6 indicate that NDSK-II promoted transendothelial migration of these cells, as was expected based on the previous results. 11, 15 However, in the presence of RAP, this effect was completely abrogated. In control experiments, RAP itself neither increased nor decreased the transmigration and the (β15-66) 2 fragment inhibited the NDSK-II-induced transmigration practically to the same degree as RAP. Altogether, these experiments indicate that RAP inhibits transendothelial migration of leukocytes induced by NDSK-II suggesting the involvement of the VLDL receptor in this process.
Evidence for the involvement of the VLDL receptor in fibrin-dependent leukocyte transmigration in vivo
To investigate the involvement of the VLDL receptor in leukocyte transmigration in vivo, we studied this process in VLDLR-deficient mice (VLDLR -/-). Using the in vivo peritonitis model, we compared infiltration of leukocytes (neutrophils) from the circulation into the peritoneum in wild-type and VLDLR-deficient mice. The experiment revealed that leukocyte transmigration in VLDLR -/-mice was moderately (by about 22%) lower than that in wild-type mice ( Figure 7A ), although the difference was not statistically significant. When both wild-type and VLDLR -/-mice were injected intravenously either with PBS (control mice) or with the (β15-66) 2 fragment prior to intraperitoneal injection of thioglycollate, this fragment inhibited leukocyte transmigration only in wild-type mice;
no effect was observed in VLDLR -/-mice. A very similar effect was observed in another experiment, in which wild-type and VLDLR -/-mice were injected with the shorter (β15-44) 2 dimer, which in our previous study 15 exhibited similar anti-inflammatory effect as the (β15-66) 2 fragment, and control mice were injected with scrambled (β15-44) 2 instead of PBS ( Figure 7B ). These results indicate that fibrin-dependent leukocyte transmigration, which in wild-type mice is inhibited by (β15-66) 2 or (β15-44) 2 , does not occur in mice lacking VLDLR. They directly confirm the involvement of the VLDL receptor in fibrin-dependent leukocyte transmigration. Moreover, they suggest that VLDLR is absolutely necessary for this process.
Discussion
Our observation that the (β15-66) 2 fragment, which mimics the fibrin βN-domains, alters the morphology of HUVEC adherens junctions formed by VE-cadherin making them more loose ( Figure   1 ) suggests that the interaction of this fragment with VE-cadherin could result in opening of these junctions and thereby promoting transendothelial migration of leukocytes. This finding is in
with the previous observations that fibrinogen or its β15-42 peptide increases permeability of HUVEC monolayer and fibrinogen induces intracellular gap formation and cytosolic relocation of VE-cadherin through the interaction of its β15-42 sequence with VE-cadherin. 27 In contrast, a recent in vivo study using two shock models revealed that β15-42 preserves endothelial barrier function by inhibiting stress-induced opening of the adherent junctions. 28 The reason for such a discrepancy is not clear and, therefore, the effect of β15-42 containing fragments on the endothelial barrier function requires further investigation. Whatever the reason is, our observation of the redistribution of VE-cadherin in HUVECs prompted us to hypothesize the involvement of a member of a RAP-dependent LDL receptor family in this process. Testing this hypothesis resulted in the discovery of a novel high affinity interaction between fibrin and the VLDL receptor that occurs through fibrin βN-domains.
Our other findings, that RAP abrogates the effect of (β15-66) 2 on the morphology of HUVECs and inhibits NDSK-II induced transendothelial migration of leukocytes, prompted us to hypothesize the involvement of fibrin-VLDLR interaction in fibrin-dependent leukocyte transmigration. Our recent study using the in vivo peritonitis model revealed that the dimeric (β15-66) 2 fragment and its truncated variant (β15-44) 2 both inhibited infiltration of leukocytes (neutrophils) from the circulation into the peritoneum, further confirming the role of fibrin or its degradation products in this process. 15 In the present study, we used this model to test the above mentioned hypothesis by studying the effect of these fragments on the infiltration of neutrophils in wild-type and VLDLR-deficient mice. Our observation that both fragments significantly inhibited neutrophil infiltration in wild-type mice while had no effect in VLDLR-deficient mice directly reactive epitopes are exposed in fibrin clots. 29 Furthermore, the VLDLR-binding site may be located in a different part of the βN-domain. Thus, the VLDL receptor should interact with both fibrin degradation products containing the βN-domains and fibrin polymers. Similarly, VE-cadherin, whose fibrin-binding site was localized in the N-terminal portion of the βN-domain, 13 should also interact with fibrin clots, although this remains to be demonstrated.
According to the current view, fibrin degradation products containing the β15-42 sequence promote leukocyte transmigration and thereby inflammation by bridging leukocytes to the endothelium through the interaction with the leukocyte receptor CD11c and endothelial cell VEcadherin and the anti-inflammatory effect of the β15-42 peptide is connected with its ability to inhibit the interaction with VE-cadherin. 4, 11, 30 Taking into account the exposure of the VE-cadherin-binding sites in fibrin clots mentioned above, one can speculate that fibrin deposited on the endothelium may also promote leukocyte transmigration. Therefore, this process may depend not only on fibrin degradation products, as was suggested earlier, 4, 11, 30 but also on fibrin, i.e. the latter may promote leukocyte transmigration by the same bridging mechanism. In the present study, we discovered that the VLDL receptor also modulates fibrin-dependent leukocyte transmigration.
Whether fibrin-VLDLR interaction contributes to bridging of leukocytes to the endothelium and acts together with fibrin-VE-cadherin interaction or this interaction is a part of another fibrin-dependent mechanism of leukocyte transmigration remains to be established.
In summary, the present study revealed that fibrin interacts with high affinity with the endothelial cell receptor VLDLR. The interaction occurs through fibrin βN-domains, is inhibited by RAP and by the dimeric fragments mimicking these domains, and is involved in fibrin-dependent Wild-type VLDLR -/-
